Our purpose is to greatly enhance the handling of critical perishable blood components such as platelets and red blood cells for blood transfusions and cell cultures for research and medical purposes.
Our competitive advantage centers on our proprietary platform technology involving the use of xenon gas to protect human cells.
In 2008 working on the methods for food preservation we came across several publications on the effect of nobel gas Xenon on biological cells. Since then, we have been on a journey to develop practical solutions for preservation of biological tissues.
Meet the Management Team
Matthew E. Colpoys
Matthew is a seasoned executive with over 30 years experience in the biopharmaceutical/medtech industry. He was a key member of the early commercial and management teams at Genentech (Sold to Roche), Pharmacia (Sold to Upjohn/Pfizer), Neurex (Sold to Elan) and Insmed. At these companies his integral participation resulted in a number of successful commercial product launches.
PhD, MBA - CTO
Ilya is R&D leader with 20+ years of experience involving new product and technology development and implementation. Prior to CPT he was a Senior Principal at GEN3 Partners, where he helped Fortune 500 companies build a process and culture for innovation. He has significant experience in delivering practical solutions that have been adopted by world's most recognized companies. With a background in bioengineering, he is an author of more than 15 patents, many articles and a textbook chapter.
DDS, PhD - CSO
Dr. Suresh is a world class scientist, with broad experience in oral surgery, immunology, diagnostics and pathology. He is an author of multiple publications and book chapters, holds several patents, and has research collaborations around the world. He holds an academic appointment at the State University of NY at Buffalo, and is licensed to practice oral surgery in the UK.